Lineage Cell Therapeutics (LCTX) Capital Expenditures (2010 - 2026)

Lineage Cell Therapeutics has reported Capital Expenditures for 17 years, with the latest figure at $70000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 27.84% year-over-year to $70000.0; the trailing twelve-month figure through Mar 2026 stood at $495000.0 (down 20.67% YoY), and the FY2025 full-year result was $522000.0, down 7.61% from the prior year.
• Capital Expenditures for Q1 2026 stood at $70000.0, down from $497000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $666000.0 in Q4 2023, with the low at -$436000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $109352.9 across 5 years, with a median of $97000.0 in 2022.
• The largest YoY upside for Capital Expenditures was 429.63% in 2022 against a maximum downside of 374.66% in 2022.
• Lineage Cell Therapeutics' Capital Expenditures stood at -$401000.0 in 2022, then surged by 266.08% to $666000.0 in 2023, then sank by 45.2% to $365000.0 in 2024, then jumped by 36.16% to $497000.0 in 2025, then plunged by 85.92% to $70000.0 in 2026.
• The last three Capital Expenditures figures came in at $70000.0 (Q1 2026), $497000.0 (Q4 2025), and -$86000.0 (Q3 2025), per Business Quant data.